
Topic
Drug Pricing
WAC, ASP, NADAC, IRA negotiated prices, inflation rebates, and drug cost trends affecting access and coverage.

Generics· June 14, 2026 · 10 min read
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Generics· June 14, 2026 · 11 min read
Single-source ophthalmic drops in the Orange Book: 67 molecules, 11% AB-substitutable
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Pricing & Access· June 13, 2026 · 14 min read
NADAC price lookup: what acquisition-cost data can and cannot say about payer spread

Pricing & Access· June 12, 2026 · 9 min read
CMS NADAC by the numbers: 696K records, median $0.19/unit, brands 81× generic
By Ran Chen#Drug Pricing#Medicaid#Formulary Strategy

Generics· June 11, 2026 · 10 min read
Orange Book therapeutic equivalence: 48K products, 55% single-source, AB dominates
By Ran Chen#ANDA Approval#Orange Book#Generic Entry

Policy· June 11, 2026 · 12 min read
US drug product landscape: 135,667 NDCs, 49,681 generics, and a 2033 format overhaul
By Ran Chen#FDA Approval#Drug Pricing#Supply Chain

Biosimilars· June 10, 2026 · 8 min read
Biosimilar competition decoded: 229 products across 20 reference drugs, one concentration
By Ran Chen#Biosimilars#Purple Book#Formulary Strategy

Policy· June 10, 2026 · 9 min read
Drug recalls by the numbers: 17,683 events, 80% Class II, and a sterility crisis

Policy· June 10, 2026 · 10 min read
Inside 20 million FAERS reports: 57% serious, Enbrel leads, death in 1.9 million
By Ran Chen#FDA Approval#Drug Pricing#Clinical Evidence

Policy· June 10, 2026 · 8 min read
The 2026–2032 patent cliff by the numbers: 11,000 patents, $200 billion at risk
By Ran Chen#Orange Book#Generic Entry#Biosimilars